加齢黄斑変性症（AMD）遺伝子治療の世界市場（～2026年）

• 英文タイトル：Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12018 • 出版社/出版日：QYResearch / 2020年11月25日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は加齢黄斑変性症（AMD）遺伝子治療のグローバル市場について調査・分析したレポートです。種類別（網膜下、硝子体内）市場規模、用途別（単剤療法、併用療法）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別加齢黄斑変性症（AMD）遺伝子治療の競争状況、市場シェア ・世界の加齢黄斑変性症（AMD）遺伝子治療市場：種類別市場規模 2015年-2020年（網膜下、硝子体内） ・世界の加齢黄斑変性症（AMD）遺伝子治療市場：種類別市場規模予測 2021年-2026年（網膜下、硝子体内） ・世界の加齢黄斑変性症（AMD）遺伝子治療市場：用途別市場規模 2015年-2020年（単剤療法、併用療法） ・世界の加齢黄斑変性症（AMD）遺伝子治療市場：用途別市場規模予測 2021年-2026年（単剤療法、併用療法） ・北米の加齢黄斑変性症（AMD）遺伝子治療市場分析：米国、カナダ ・ヨーロッパの加齢黄斑変性症（AMD）遺伝子治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの加齢黄斑変性症（AMD）遺伝子治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の加齢黄斑変性症（AMD）遺伝子治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの加齢黄斑変性症（AMD）遺伝子治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：RetroSense Therapeutics、REGENXBIO、AGTC ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market’s growth.

Market Analysis and Insights: Global Gene Therapy for Age-related Macular Degeneration Market
The global Gene Therapy for Age-related Macular Degeneration market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Gene Therapy for Age-related Macular Degeneration Scope and Market Size
Gene Therapy for Age-related Macular Degeneration market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gene Therapy for Age-related Macular Degeneration market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
RetroSense Therapeutics
REGENXBIO
AGTC
…

Market segment by Type, the product can be split into
Subretinal
Intravitreal
Market segment by Application, split into
Monotherapy
Combination Therapy

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
1.4 Market by Type
1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Subretinal
1.4.3 Intravitreal
1.5 Market by Application
1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2020 VS 2026
1.5.2 Monotherapy
1.5.3 Combination Therapy
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2015-2026)
2.2 Global Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions
2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Share by Regions (2015-2020)
2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Gene Therapy for Age-related Macular Degeneration Market Growth Strategy
2.3.6 Primary Interviews with Key Gene Therapy for Age-related Macular Degeneration Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Market Size
3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2015-2020)
3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2015-2020)
3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio
3.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2019
3.3 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
3.4 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
3.5 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2015-2020)
4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)
5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
6.2 Gene Therapy for Age-related Macular Degeneration Key Players in North America (2019-2020)
6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

7 Europe
7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
7.2 Gene Therapy for Age-related Macular Degeneration Key Players in Europe (2019-2020)
7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

8 China
8.1 China Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
8.2 Gene Therapy for Age-related Macular Degeneration Key Players in China (2019-2020)
8.3 China Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
8.4 China Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

9 Japan
9.1 Japan Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
9.2 Gene Therapy for Age-related Macular Degeneration Key Players in Japan (2019-2020)
9.3 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
9.4 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
10.2 Gene Therapy for Age-related Macular Degeneration Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
10.4 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

11 India
11.1 India Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
11.2 Gene Therapy for Age-related Macular Degeneration Key Players in India (2019-2020)
11.3 India Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
11.4 India Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size (2015-2020)
12.2 Gene Therapy for Age-related Macular Degeneration Key Players in Central & South America (2019-2020)
12.3 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020)
12.4 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 RetroSense Therapeutics
13.1.1 RetroSense Therapeutics Company Details
13.1.2 RetroSense Therapeutics Business Overview
13.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction
13.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020))
13.1.5 RetroSense Therapeutics Recent Development
13.2 REGENXBIO
13.2.1 REGENXBIO Company Details
13.2.2 REGENXBIO Business Overview
13.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction
13.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020)
13.2.5 REGENXBIO Recent Development
13.3 AGTC
13.3.1 AGTC Company Details
13.3.2 AGTC Business Overview
13.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction
13.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020)
13.3.5 AGTC Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Gene Therapy for Age-related Macular Degeneration Key Market Segments
Table 2. Key Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
Table 3. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Subretinal
Table 6. Key Players of Intravitreal
Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2015-2020)
Table 11. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Gene Therapy for Age-related Macular Degeneration Market Growth Strategy
Table 17. Main Points Interviewed from Key Gene Therapy for Age-related Macular Degeneration Players
Table 18. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2015-2020) (Million US$)
Table 19. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2015-2020)
Table 20. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2019)
Table 21. Global Gene Therapy for Age-related Macular Degeneration by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service
Table 24. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Type (2015-2020)
Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2021-2026)
Table 29. Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Application (2015-2020)
Table 30. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 31. Global Gene Therapy for Age-related Macular Degeneration Market Size Share by Application (2021-2026)
Table 32. North America Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 34. North America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 35. North America Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 36. North America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 37. North America Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 38. Europe Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 40. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 42. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 44. China Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 45. China Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 46. China Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 47. China Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 48. China Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 49. China Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 50. Japan Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 52. Japan Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 54. Japan Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 58. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 60. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 62. India Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 63. India Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 64. India Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 65. India Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 66. India Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 67. India Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Gene Therapy for Age-related Macular Degeneration Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Gene Therapy for Age-related Macular Degeneration Market Share (2019-2020)
Table 70. Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Gene Therapy for Age-related Macular Degeneration Market Share by Type (2015-2020)
Table 72. Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Gene Therapy for Age-related Macular Degeneration Market Share by Application (2015-2020)
Table 74. RetroSense Therapeutics Company Details
Table 75. RetroSense Therapeutics Business Overview
Table 76. RetroSense Therapeutics Product
Table 77. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020) (Million US$)
Table 78. RetroSense Therapeutics Recent Development
Table 79. REGENXBIO Company Details
Table 80. REGENXBIO Business Overview
Table 81. REGENXBIO Product
Table 82. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020) (Million US$)
Table 83. REGENXBIO Recent Development
Table 84. AGTC Company Details
Table 85. AGTC Business Overview
Table 86. AGTC Product
Table 87. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2015-2020) (Million US$)
Table 88. AGTC Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2020 VS 2026
Figure 2. Subretinal Features
Figure 3. Intravitreal Features
Figure 4. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2020 VS 2026
Figure 5. Monotherapy Case Studies
Figure 6. Combination Therapy Case Studies
Figure 7. Gene Therapy for Age-related Macular Degeneration Report Years Considered
Figure 8. Global Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions: 2020 VS 2026
Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2019
Figure 13. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2019
Figure 15. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Bottom-up and Top-down Approaches for This Report
Figure 23. Data Triangulation
Figure 24. Key Executives Interviewed

---